FTSE 100: Index falls as earnings results weigh; pound below $1.33, Bodycote soars
Investing.com - CapsoVision Inc (NASDAQ:CV) received its first analyst coverage Monday as Roth/MKM initiated research with a Buy rating and a $6.00 price target, representing a 50% upside from the current price of $4.00. The company, with a market capitalization of $186 million, is currently rated as fairly valued according to InvestingPro analysis.
The medical technology company specializes in capsule endoscopy systems for gastrointestinal imaging, with its current platform approved for small bowel examinations. InvestingPro data shows the company maintains a healthy gross profit margin of 54% and a strong current ratio of 3.87, indicating solid operational efficiency and liquidity.
Roth/MKM projects 19.5% revenue growth for CapsoVision in 2025, driven by its existing small bowel indication applications.
The company recently submitted a 510(k) application to the FDA seeking approval for colon screening, which represents a substantially larger market opportunity.
Roth/MKM expects the potential colon indication approval to "significantly boost revenue growth in 2026 and beyond" as CapsoVision continues developing its imaging technology and artificial intelligence capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.